H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $75 from $60 and keeps a Buy rating on the shares. The firm views Eli Lilly’s (LLY) orforglipron data from the ATTAIN-1 study showing 12.4% body weight loss from the baseline as “encouraging” for Structure’s aleniglipron. Given Lilly’s data, aleniglipron “may emerge as a strong contender for best-in-class profile based on several differentiating factors,” the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target lowered to $44 from $60 at Leerink
- Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf